BACKGROUND: Chemotherapy-associated neutropenia has been reported to be a pharmacodynamic marker of response in some advanced solid tumors. Factors that accelerate drug clearance lead to lower plasma concentrations and toxicity, including neutropenia. Smoking accelerates the metabolism of several drugs, including chemotherapy. We sought to study the effects of smoking on gemcitabine-induced neutropenia in this retrospective study. METHODS: Smoking status and neutropenia along with other clinical parameters were recorded in 151 patients receiving first-line gemcitabine-based chemotherapy for advanced solid tumors. RESULTS: Tumor types included breast (9.3%), lung (4.6%), pancreatobiliary (70.9%), or other/unknown primary cancer (15.2%). Logistic regression showed that never smokers had increased neutropenia versus current smokers (odds ratio: 3.5; 95% confidence interval, CI: 1.1-11.4). A 5-unit increase in pack-years reduced the odds of having higher neutropenia toxicity by 6.3% (95% CI 12 to 1%; p = 0.036). CONCLUSION: Smokers had less neutropenia than nonsmokers, a finding that was more pronounced with increasing pack-years. This pharmacodynamic marker of gemcitabine-induced neutropenia may result in less efficacy of gemcitabine. Future prospective trials should correlate smoking, metabolizing phenotype, neutropenia, and response to gemcitabine therapy.
BACKGROUND: Chemotherapy-associated neutropenia has been reported to be a pharmacodynamic marker of response in some advanced solid tumors. Factors that accelerate drug clearance lead to lower plasma concentrations and toxicity, including neutropenia. Smoking accelerates the metabolism of several drugs, including chemotherapy. We sought to study the effects of smoking on gemcitabine-induced neutropenia in this retrospective study. METHODS: Smoking status and neutropenia along with other clinical parameters were recorded in 151 patients receiving first-line gemcitabine-based chemotherapy for advanced solid tumors. RESULTS:Tumor types included breast (9.3%), lung (4.6%), pancreatobiliary (70.9%), or other/unknown primary cancer (15.2%). Logistic regression showed that never smokers had increased neutropenia versus current smokers (odds ratio: 3.5; 95% confidence interval, CI: 1.1-11.4). A 5-unit increase in pack-years reduced the odds of having higher neutropenia toxicity by 6.3% (95% CI 12 to 1%; p = 0.036). CONCLUSION: Smokers had less neutropenia than nonsmokers, a finding that was more pronounced with increasing pack-years. This pharmacodynamic marker of gemcitabine-induced neutropenia may result in less efficacy of gemcitabine. Future prospective trials should correlate smoking, metabolizing phenotype, neutropenia, and response to gemcitabine therapy.
Authors: Marta Hamilton; Julie L Wolf; Jason Rusk; Shannon E Beard; Gary M Clark; Karsten Witt; Pablo J Cagnoni Journal: Clin Cancer Res Date: 2006-04-01 Impact factor: 12.531
Authors: Jessica M van der Bol; Ron H J Mathijssen; Walter J Loos; Lena E Friberg; Ron H N van Schaik; Maja J A de Jonge; André S Th Planting; Jaap Verweij; Alex Sparreboom; Floris A de Jong Journal: J Clin Oncol Date: 2007-06-11 Impact factor: 44.544
Authors: Avrum Spira; Jennifer Beane; Vishal Shah; Gang Liu; Frank Schembri; Xuemei Yang; John Palma; Jerome S Brody Journal: Proc Natl Acad Sci U S A Date: 2004-06-21 Impact factor: 11.205
Authors: M L Levitt; B Kassem; W E Gooding; L M Miketic; R J Landreneau; P F Ferson; R Keenan; S A Yousem; C A Lindberg; M R Trenn; R S Ponas; P Tarasoff; J M Sabatine; D Friberg; T L Whiteside Journal: Lung Cancer Date: 2004-03 Impact factor: 5.705
Authors: George E Fragoulis; Caron Paterson; Ashley Gilmour; Mohammad H Derakhshan; Iain B McInnes; Duncan Porter; Stefan Siebert Journal: RMD Open Date: 2018-10-08